Study of Tofacitinib in Refractory Dermatomyositis: An Open‐Label Pilot Study of Ten Patients

Small case series found that 50% experienced a moderate improvement, and 50% a minimal improvement in disease activity (according to ACR/EULAR myositis response criteria) after 12 weeks of tofacitinib 11 mg daily. Authors report response was predominantly in the skin.

Source:

Arthritis & Rheumatology